AbbVie's Atogepant Hits Primary Endpoint in Phase 3 Menstrual Migraine Trial
ABBV sits 32% above its 52-week low of $190.75 on light trading volume (0.2× avg).
Summary
AbbVie's Phase 3 LUNA trial for atogepant in menstrual migraine met its primary endpoint, showing a 0.80-day greater reduction in perimenstrual migraine days versus placebo. All eight secondary endpoints also achieved statistical significance. Atogepant is already approved in 60 countries as QULIPTA/AQUIPTA, so this data could support label expansion into menstrual migraine, a common and underserved indication. The stock was up 0.39% on the news, a modest reaction for a large-cap pharma. This follows AbbVie's recent $10.9B Apogee acquisition and positive regulatory updates for RINVOQ and TEPKINLY, reinforcing its immunology and migraine franchise momentum.
At the time of this announcement, ABBV was trading at $252.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $446.1B. The 52-week trading range was $190.75 to $267.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.